You are here: Home » Companies » News
Business Standard

Glenmark Pharma gets USFDA nod for seizure treatment drug

Shares of Glenmark Pharmaceuticals were trading 1.02% higher at Rs 656.10 apiece on the BSE

Press Trust of India  |  New Delhi 

Photo: Reuters
Photo: Reuters

Pharmaceuticals has received a tentative nod from the US health regulator for extended release capsules, used to treat certain types of

The approved product is a generic version of Upsher-Smith Laboratories, LLC's extended release capsules.

Pharmaceuticals Inc USA has been granted tentative approval by the Food and Drug Administration for extended release capsules in the strength of 25 mg, 50 mg, 100 mg, 150 mg and 200 mg, the company said in a BSE filing on Thursday.

Quoting IQVIA sales data for the 12-month period ended November 2018, Pharmaceuticals said, extended release capsules market achieved annual sales of approximately $84 million.

The company's current portfolio consists of 148 products authorised for distribution in the US market and 54 abbreviated new drug applications (ANDAs) pending approval with the

Shares of were trading 1.02 per cent higher at Rs 656.10 apiece on the BSE.

First Published: Thu, January 24 2019. 10:35 IST